🇺🇸 FDA
Pipeline program

Olverembatinib

HQP1351AG301

Phase 3 small_molecule active

Quick answer

Olverembatinib for Ph+ ALL is a Phase 3 program (small_molecule) at Ascentage Pharma Group with 1 ClinicalTrials.gov record(s).

Program details

Company
Ascentage Pharma Group
Indication
Ph+ ALL
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials